U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT07583290) titled 'Artificial Intelligence for Ulinastatin Responder Outcome & Risk Assessment in CPB' on March 20.
Brief Summary: This is a multicenter, retrospective, real-world observational study aimed at developing and validating an artificial intelligence-based tool for identifying ulinastatin treatment responders and risk stratification in cardiac surgery patients undergoing cardiopulmonary bypass (CPB).
Ulinastatin, a glycoprotein extracted from human urine, has shown potential benefits in reducing postoperative complications and inflammatory responses in cardiac surgery. However, evidence supporting its efficacy and optimal application in spe...